Reckitt Benckiser Group PLC

Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Johann A. Benckiser in 1823 and is headquartered in Slough, the United Kingdom.

Reckitt Benckiser Group plc (RBGPF) CEO Laxman Narasimhan on Q3 2019 Trading Update - Call Transcript

Reckitt Benckiser Group Plc lowered its sales forecast on slower demand for flu medicines in the U.S. and baby formula in China as challenges mount during Chief Executive Officer Laxman.

Reckitt Benckiser's New CEO Lowers Sales Goal In Company Reset

Reckitt Benckiser Group plc (RBGPF) CEO Rakesh Kapoor on Q2 2019 Results - Earnings Call Transcript

Making misleading claims about the safety and effectiveness of drugs to convince doctors to write more prescriptions has long been one of the pharmaceutical industry’s favored methods of driving profits.

What Reckitt’s $1.4 Billion Settlement Says About The Pharma Industry

Microsoft

Philip Morris

SAP SE

Unilever

Fund’s top buys include Microsoft and Lysol parent Reckitt Benckiser.

MS Global Franchise Fund’s Top 5 High-Conviction Trades as of 1st Quarter

Reckitt Benckiser has agreed to pay up to $1.4 billion to resolve U.S. claims that its former pharmaceuticals business Indivior before it was spun out of the company carried out an illegal scheme to boost sales of an opioid addiction treatment.

Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes

Drugmaker Indivior Plc said on Thursday its former parent Reckitt Benckiser's $1.4 billion settlement with authorities in the United States was separate to its ongoing legal proceedings.

Indivior says Reckitt settlement in U.S. unrelated to its cases

Nurofen maker reaches deal with US over alleged fraudulent marketing of Suboxone

Reckitt Benckiser to pay $1.4bn fine over opioid treatment sales

Consumer goods giant Reckitt Benckiser said it has agreed to pay up to $1.4bn to settle US investigations into the sale and marketing of an opioid addiction treatment by its former pharmaceuticals business Indivior.

Reckitt in $1.4bn settlement over US opioid treatment probe

Britain's Reckitt Benckiser (RB)  said it would pay up to $1.4 billion to resolve all U.S. federal investigations into the firm in connection with the sales and marketing of Suboxone Film by its former prescription pharmaceuticals business Indivior.

UK's Reckitt Benckiser to pay up to $1.4 billion to end Indivior probe

Consumer goods group Reckitt Benckiser has picked PepsiCo executive Laxman Narasimhan as its next chief executive, becoming the latest industry heavyweight to turn to a company outsider to tackle faltering growth and new media-savvy rivals.

News for Reckitt Benckiser Group PLC Stock (RBGLY)